Dorsey & Whitney Trust’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.2M | Sell |
32,618
-1,751
| -5% | -$83K | 0.07% | 255 |
|
|
2025
Q4 | $1.75M | Buy |
34,369
+5,500
| +19% | +$281K | 0.09% | 182 |
|
|
2025
Q3 | $1.6M | Sell |
28,869
-722
| -2% | -$42.3K | 0.08% | 191 |
|
|
2025
Q2 | $2.04M | Sell |
29,591
-955
| -3% | -$65K | 0.11% | 164 |
|
|
2025
Q1 | $2.12M | Sell |
30,546
-948
| -3% | -$78.3K | 0.12% | 152 |
|
|
2024
Q4 | $2.71M | Buy |
31,494
+136
| +0.4% | +$14.7K | 0.15% | 129 |
|
|
2024
Q3 | $3.73M | Buy |
31,358
+1,382
| +5% | +$184K | 0.2% | 110 |
|
|
2024
Q2 | $4.28M | Sell |
29,976
-1,739
| -5% | -$230K | 0.3% | 87 |
|
|
2024
Q1 | $4.07M | Buy |
31,715
+339
| +1% | +$40.4K | 0.28% | 87 |
|
|
2023
Q4 | $3.25M | Buy |
31,376
+1,142
| +4% | +$113K | 0.25% | 101 |
|
|
2023
Q3 | $2.75M | Sell |
30,234
-80
| -0.3% | -$7.05K | 0.24% | 103 |
|
|
2023
Q2 | $2.45M | Buy |
30,314
+1,516
| +5% | +$124K | 0.2% | 115 |
|
|
2023
Q1 | $2.29M | Buy |
28,798
+294
| +1% | +$20.8K | 0.21% | 109 |
|
|
2022
Q4 | $1.93M | Buy |
28,504
+2,902
| +11% | +$170K | 0.19% | 121 |
|
|
2022
Q3 | $1.28M | Buy |
25,602
+514
| +2% | +$27.5K | 0.13% | 150 |
|
|
2022
Q2 | $1.4M | Buy |
25,088
+638
| +3% | +$35.4K | 0.14% | 143 |
|
|
2022
Q1 | $1.36M | Buy |
24,450
+1,550
| +7% | +$79.5K | 0.12% | 161 |
|
|
2021
Q4 | $1.28M | Buy |
22,900
+698
| +3% | +$37.8K | 0.11% | 170 |
|
|
2021
Q3 | $1.07M | Sell |
22,202
-22
| -0.1% | -$1.06K | 0.1% | 184 |
|
|
2021
Q2 | $930K | Buy |
22,224
+94
| +0.4% | +$3.64K | 0.09% | 195 |
|
|
2021
Q1 | $746K | Buy |
22,130
+1,318
| +6% | +$46.9K | 0.07% | 219 |
|
|
2020
Q4 | $727K | Buy |
20,812
+54
| +0.3% | +$1.87K | 0.08% | 203 |
|
|
2020
Q3 | $720K | Buy |
20,758
+18
| +0.1% | +$600 | 0.1% | 184 |
|
|
2020
Q2 | $680K | Buy |
20,740
+40
| +0.2% | +$1.28K | 0.1% | 185 |
|
|
2020
Q1 | $624K | Sell |
20,700
-310
| -1% | -$9.23K | 0.11% | 166 |
|
|
2019
Q4 | $606K | Sell |
21,010
-4
| -0% | -$111 | 0.08% | 196 |
|
|
2019
Q3 | $543K | Sell |
21,014
-386
| -2% | -$9.76K | 0.08% | 207 |
|
|
2019
Q2 | $546K | Buy |
21,400
+94
| +0.4% | +$2.32K | 0.08% | 198 |
|
|
2019
Q1 | $557K | Buy |
21,306
+7,852
| +58% | +$193K | 0.09% | 185 |
|
|
2018
Q4 | $310K | Buy |
13,454
+840
| +7% | +$18.7K | 0.05% | 248 |
|
|
2018
Q3 | $297K | Buy |
12,614
+1,494
| +13% | +$36.5K | 0.05% | 285 |
|
|
2018
Q2 | $257K | Sell |
11,120
-90
| -0.8% | -$2.14K | 0.04% | 295 |
|
|
2018
Q1 | $276K | Sell |
11,210
-334
| -3% | -$8.77K | 0.05% | 259 |
|
|
2017
Q4 | $310K | Buy |
+11,544
| New | +$294K | 0.06% | 230 |
|
|
2016
Q3 | – | Sell |
-9,244
| Closed | -$248K | – | 312 |
|
|
2016
Q2 | $248K | Buy |
+9,244
| New | +$254K | 0.06% | 221 |
|
Other funds holding NVO
DAM
F
Dorsey & Whitney Trust's NVO Position: Q1 2026 in Review
Dorsey & Whitney Trust reduced its Novo Nordisk (NVO) stake by 5.1% in Q1 2026, selling an estimated $83K and leaving 32,618 shares worth $1.2M. The position accounts for 0.07% of the portfolio, ranked #255.
Dorsey & Whitney Trust first reported a position in NVO in Q2 2016 and has held it in 35 quarters since. The position peaked at $4.28M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Dorsey & Whitney Trust held 32,618 shares of Novo Nordisk worth $1.2M as of Q1 2026.
- Dorsey & Whitney Trust sold 1,751 Novo Nordisk shares in Q1 2026, an estimated $83K.
- Novo Nordisk made up 0.07% of Dorsey & Whitney Trust's portfolio in Q1 2026, its #255 holding.
- Dorsey & Whitney Trust first reported a position in Novo Nordisk in Q2 2016 and has held it in 35 quarters since.
- Dorsey & Whitney Trust's Novo Nordisk position peaked at $4.28M in Q2 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Dorsey & Whitney Trust's 13F filing for Q1 2026, filed 14 May 2026.